Is the combination of ASTX727 and talazoparib being tested for HER2-negative Breast Cancer?
The combination of ASTX727 and talazoparib is being studied in specific types of HER2-negative breast cancer. These include triple-negative breast cancer (TNBC) and hormone-resistant breast cancer (HRBC).
In these studies, researchers are looking at how adding a DNA methyltransferase inhibitor (ASTX727) to a PARP inhibitor (talazoparib) might improve treatment outcomes for patients who have already received other treatments.
What the research says
A phase 1 trial evaluated the combination of ASTX727 and talazoparib in patients with previously treated triple-negative metastatic breast cancer or hormone-resistant breast cancer 4. These types of cancers are categorized as HER2-negative. The study aimed to see if combining these two drugs could create a "BRCAness phenotype," which is a condition that makes cancer cells more sensitive to PARP inhibitors 4.
While the trial was designed to test this specific combination in HER2-negative settings, early results showed that 34 evaluable patients were treated across eight dose cohorts. The study noted common side effects like myelosuppression (bone marrow suppression), including neutropenia (low white blood cell count) and anemia 4. In the trial, there were no objective responses, though some patients had stable disease for more than four months 4.
Other research in HER2-negative breast cancer has explored different treatments. For example, one study looked at olaparib as a treatment for advanced HER2-negative breast cancer to see if specific biomarkers could predict who would benefit most from the drug 6. Another trial investigated gedatolisib combined with other drugs for hormone receptor-positive, HER2-negative advanced breast cancer 3.
What to ask your doctor
- Is the combination of ASTX727 and talazoparib currently available as a standard treatment for my specific type of HER2-negative breast cancer?
- What are the potential side effects of combining a DNA methyltransferase inhibitor with a PARP inhibitor?
- Are there clinical trials currently recruiting patients for this specific drug combination?
- How does this combination compare to other treatments for triple-negative or hormone-resistant breast cancer?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.